Clinical trials: sponsored by Virginia Commonwealth University
- Sponsor Virginia Commonwealth University
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Muscular Dystrophies, Limb Girdle Muscular Dystrophy
Biomarker Development in LGMD2i
The overall goal of this natural history study is to define the key LGMD2i phenotypes as measured by standard clinical outcome assessments (COAs), and to validate a muscle biomarker for LGMD2i to support therapeutic development.
- Trial name
- MLB-01-001 (NCT04202627)
- Where
- 11 sites in United States, Denmark
- Volunteers
- 101 people
- Sponsor
- ML Bio Solutions, Inc.
Vital Sign Monitoring
Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients
This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring.
- Trial name
- NCT03356184
- Testing
- The Rhea Vital Sign Vigilance Device Group, The Earlysense System Device Group
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Darma Inc.
Vital Sign Monitoring
Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients Patients
This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring.
- Trial name
- NCT03332147
- Testing
- Investigational Group, reference group-Earlysense system
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Darma Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese
Nonalcoholic fatty liver disease (NAFLD) is a progressive liver disease ranging from simple steatosis to cirrhosis of the liver.
- Trial name
- NCT03282305
- Volunteers
- 5,000 people
- Sponsor
- Great China Fatty Liver Consortium Limited